Bellamy’s Australia enters into $1.5b takeover scheme with China Mengniu Dairy Company

16SepSeptember 16, 2019

Bellamy’s Australia enters into $1.5b takeover scheme with China Mengniu Dairy Company

Bellamy’s Australia (ASX:BAL) has entered into a Scheme Implementation Deed under which it is proposed that China Mengniu Dairy Company will acquire 100 per cent of the issued share capital of Bellamy’s via a scheme of arrangement.

If the Scheme proceeds, it is intended that Bellamy’s shareholders will receive a total of $13.25 cash per share.

The takeover offers a significant 59 per cent premium to the last closing price for Bellamy's shares.

The board of Bellamy's has unanimously recommended that shareholders vote in favour of the offer.

Shares in Bellamy’s (ASX:BAL) are trading 53.97 per cent higher to $12.81.

Copyright 2019 – Finance News Network

Source: Finance News Network

07OctOctober 7, 2022

Stocks of the Hour: Tamboran Resources, Kula Gold

07 Oct 2022 - A snapshot of the stocks on the move featuring Tamboran Resources (ASX:TBN) and Kula Gold (ASX:KGD).

11MarMarch 11, 2020

Synlait Milk (ASX:SM1) to acquire neighbouring Dunsandel farmland

11 Mar 2020 - Synlait Milk (ASX:SM1) is to acquire farmland adjacent to its Dunsandel facility in New Zealand for $25.7 million.

21AprApril 21, 2020

Premier Investments (ASX:PMV) to keep stores closed for two more weeks

21 Apr 2020 - Premier Investments (ASX:PMV) says all its stores will remain closed until May 11 after having no choice but to close them on 22nd April due to the coronavirus pandemic.

08JulJuly 8, 2020

Splitit Payments (ASX:SPT) see record growth in Q2 FY20

08 Jul 2020 - Installment payment company Splitit Payments (ASX:SPT) has posted record Merchant Sales Volume up 176 per cent on Q1 FY20 and up 260 per cent over Q2 FY19, due to the addition of new large merchants.

16MarMarch 16, 2021

Starpharma (ASX:SPL) reports DEP HER2-lutetium shows potent anticancer effect

16 Mar 2021 - Starpharma (ASX:SPL) says its second radiopharmaceutical candidate, DEP HER2-lutetium, achieved potent and durable anticancer activity, with complete tumour regression, outperforming Herceptin labelled with lutetium, in a breast cancer model.